RAREUltragenyx Pharmaceutical Inc.
$15.65-54% 1Y
$15.65
$12.9052 weeks$36.54
Is the price fair?
What RARE's price assumes
Ultragenyx Pharmaceutical Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 4.74× revenue.
4.74
Price / sales · no P/E: the last twelve months did not end in a profit
Details›
- EV / EBIToperating margin −74%: the multiple describes the denominator
- not meaningful
- Market capitalisation98.6 million shares, counted Jul 31, 2026
- $1.54B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks